Ruti Aga's Six Years: A Forged Prescription, A Clinic That Never Existed, And The Drug Every Report Got Wrong

One day in March, at a half marathon in China, Ruti Aga crossed the finish line first. You will not find that race's time in any report. No split, no field strength, no official mark. What survives is a sample — and the paperwork that followed it. When road-running coverage loses a number and replaces it with a prescription slip, the real story is not in the result but in the conditions gathered before it.

For forty-six years I have written not results but the conditions behind results. Those eleven seconds of silence I left on the microphone after Jyotirmoyee Sikdar's race in Bangkok taught me more than any question I ever asked. That same silence now tells me that in Ruti Aga's case, one word has gone missing from the noise — the drug's actual name.

The athlete who was sanctioned was no ordinary runner

The foundation of Ruti Aga's career is not what the papers wrote last week. It is the 2026 Tokyo Marathon, which she won. A year earlier, in Berlin, she finished second — roughly 2:18:34. In Tokyo, roughly 2:20:40. In total, three second-place finishes at World Marathon Majors. This is not the record of a rising talent; it is the record of an athlete who stayed steady, for years, just beneath the top layer of elite marathon running.

At 32, her position was clear — at the end of a peak, at the start of decline. For a 2:18–2:20 woman, this is the turn where every race becomes necessary to hold a place in the big Majors, and every race carries an appearance-fee calculation. That is the economic pressure no anti-doping ruling ever acknowledges and which sits behind every case.

In my private ledger (which I have kept since Athens 2026, when nobody asked about the single kidney behind Anju Bobby George's 6.83m), three things are filed for every athlete: employer, source of monthly income, and whose medical support. In Aga's case the third column was empty. That emptiness is the real cause of this whole case.

The drug's name, which every report got wrong

Here I must be precise and firm, because this one detail has twisted the entire story. The media wrote that Aga faced a "prohibited steroid" case. This is technically wrong. Methylprednisolone is a glucocorticoid, class S9 on the WADA Prohibited List — it is not an anabolic steroid (class S1). That distinction does not change the sanction arithmetic; it changes the entire possibility of a defence.

Under the current WADA List, S9 glucocorticoids are prohibited in-competition only, and only by injection, oral, or rectal routes. This means a therapeutic dose given into the knee, out of competition, is entirely legal. It becomes a violation only if residues are present in a sample taken in competition. The rule tightened further in 2026, and road-running cases in this class have climbed steadily since.

What this single fact does to the whole case

A road race's testing window opens at 23:59 the day before the race. So if someone took a knee injection days earlier and residues survived to race day, a case is built. But the defence path existed — medical documentation, route clarification, and timing. Real treatment would have been defended with real records.

Here the story turns. The prescription submitted was forged. The clinic named on it did not exist. The person who wrote it was a family member with no medical registration, who claimed to have used "an old prescription pad from a former workplace." The clinic that supposedly issued the pad stated plainly — this is not our pad, this is not our prescription.

Three independent verification failures, on one slip.

The six-year arithmetic: two plus four

The sanction architecture is standard, not exceptional. Two years for the presence violation, and four years for tampering — six in total. Four years is the Code's standard tampering sanction.

This arithmetic tells us something essential. In setting two years, the panel did not find serious fault on Aga's part — this was a "Specified Substance" finding without proven intent, otherwise the period would have been longer. But the panel also rejected the "No Significant Fault" mitigation — otherwise the presence sanction would have dropped below two years.

And here is a paradox worth noting. Forged documents are themselves evidence of concealment intent. Yet that intent did not escalate the presence sanction — it simply added a separate four-year penalty on top. That is the limit of the Code's architecture: intent does not lengthen the first offence, it becomes a separate offence.

The defence that could have survived, destroyed by a forged slip

Let us say it plainly. Methylprednisolone has no proven endurance benefit. It is not the drug that wins marathons. It is an anti-inflammatory that reduces swelling and pain — meaning, for a runner with an injured knee, it is a means of staying able to run, not a source of strength.

This is why the case is not a "doping" story but an injury-management story. A 32-year-old marathoner whose knee kept troubling her, for whom running is income itself, faced the question: run through the pain, or get treated? And the correct route was either a Therapeutic Use Exemption (TUE), or timing the injection early enough that no residue survived.

Neither happened. Instead, a prescription was manufactured.

And here my ledger entry becomes clearest: Aga had no credentialed team physician. Her "doctor" was a family member. This is not a filing error — it is the signature of a system in which the athlete handles her own medicine alone, informally, and in the dark.

Ethics versus proportion: why six years unsettles

Now the turn that makes this story easiest to simplify and hardest to settle. Six years for a glucocorticoid — a drug with no proven endurance benefit. It sounds severe, and it will make this case a stage on which two arguments meet.

On one side: see how strict the AIU is — this is the price of forging documents. On the other: for a drug that wins no races, a sanction of this size against East African road runners signals a disproportionate, unequal enforcement.

I will not draw a one-sided conclusion, because my method is system-first. The truth is that two things are simultaneously correct. First — fabricating medical documents is a serious, deliberate act, and it had to be sanctioned. Second — the sanction feels so heavy because the real offence was not the drug but the injury; and the real failure lay not with the athlete but with the empty support system around her.

The layers of wrongdoing are distinct, and they must be weighed separately.

The age boundary: 32 to 38

The ban runs from 10 September, for six years. That is, until roughly age 38, Aga remains outside the ring. In that one sentence lies the end of her elite career.

The depth of Ethiopian women's marathon running cannot be measured by any single name. There, sub-2:16 runners fail to make the national team. A 2:18–2:20 athlete — who would be an Olympic medal contender for any other nation — is part of a crowd. In that crowd, at 38, with a doping record, there is no road back. The ban is six years on paper; in reality it is lifetime.

And all this for what reason? Not the drug. The paperwork.

What the backdating gives — nothing

It is said that provisional suspension time counts toward the ban, offering the athlete some relief. This is a procedural benefit, not real relief. The time she had already spent out was simply folded into the full sanction. No saving in the count, none in time.

Likewise, it must be made clear that the March race result and its prize money are almost certainly voided. This is standard AIU practice. Yet none of it appears in the original report. These are the documentary gaps that trouble me in every case: what is written is visible, but the real story hides in what is left out.

What survives of the 2026 Tokyo title

Here is a fact nobody said loudly. The March race was in a different year. Absent a finding of earlier use, all results before that date — including the 2026 Tokyo Marathon title — are not automatically annulled. That record stays in her name.

This is the strange part of the small world I have inhabited for four decades. We erase an athlete entirely over one decision, and then quietly keep her greatest moment in the same list of names we do not remember. Who becomes a hero and who becomes a footnote is decided not by time — it is decided by archival politics.

The real warning: the economic pressure of success

China's label races form a separate economic tier for East African marathoners — between Majors, good appearance fees, low-risk races. But that same tier has now become the AIU's highest-yield testing ground. The appearance-fee economy and the testing economy are colliding in the same races.

So Aga's case is not isolated. It belongs to a recognizable family of cases where a substance violation is compounded by a fabricated or altered explanation. And when the explanation itself becomes the case, the question is no longer medical — it is document verification. The lever of enforcement has shifted from "detection" to "checking papers."

This is the silent shift I hear most in this case. And I have the documentary evidence — three separate verification failures, on one athlete's one treatment. A clinic that did not exist, a doctor with no registration, a pad its own issuer disowned. This is not naivety. It is the post-mortem of a whole medical economy.

What comes next: a new line in the ledger

When I close Ruti Aga's entry in my ledger, I do not write only six years. I write: knee — unverified, untreated, under-documented. I write: team physician — absent. I write: TUE — never applied for. And at the bottom I write: the one defence with a chance of being real was made fake.

This case is a lesson for the mothers who send their daughters to the altitude camps of East Africa — teach them that the difference between pain and treatment lives in a document, not a statement. And it is a warning to agents, managers, and those structures that treat a runner's injury as "ignorable." You do not need doping to end an athlete. Sometimes an empty clinic, an unqualified "doctor," and an over-trusted knee are enough.

Before the medal there is a body keeping a secret. If that body could speak openly, perhaps no slip would be made, and no six years written.

The question is not whether Aga wins — that chapter is closed. The question is whether the next runner, whose knee will hurt and who will also have a "doctor" for a relative, will find a real clinic, or return to that same old pad. The answer depends on whether we read this case as news of a sanction, or as the failure of a medical system.